4.0 Article

Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials

期刊

OPHTHALMIC SURGERY LASERS & IMAGING RETINA
卷 47, 期 5, 页码 426-435

出版社

SLACK INC
DOI: 10.3928/23258160-20160419-05

关键词

-

资金

  1. Alimera Sciences
  2. Aerie Pharmaceuticals
  3. Alcon Laboratories
  4. Glaukos
  5. InnFocus
  6. AqueSys
  7. National Eye Institute
  8. Allergan
  9. Aerpio Therapeutics
  10. Genentech
  11. Genzyme
  12. GlaxoSmithKline
  13. Oxford Biomedica
  14. Regeneron
  15. Roche

向作者/读者索取更多资源

BACKGROUND AND OBJECTIVE: To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes. PATIENTS AND METHODS: Best-corrected visual acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study charts or electronic VA testers. Goldmann applanation tonometry was used to measure IOP. RESULTS: Elevated IOP was more common in FAc-versus sham control-treated patients. Medication, and less often trabeculoplasty or surgery, was used to lower IOP without affecting VA outcomes. No patient treated with 0.2 mu g/day FAc who received prior ocular steroid required IOP-lowering surgery. CONCLUSION: Elevated IOP may occur following FAc implant receipt; however, in the present study, it was manageable and did not impact vision outcomes. Patients previously treated with ocular steroid did not require IOP-lowering surgery following 0.2 mu g/day FAc implant administration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据